Nutanix Inc vs Tilray Brands Inc — how do they compare? Nutanix Inc trades at $67.39 (market cap $18.24B), while Tilray Brands Inc trades at $4.21 (market cap $591.60M). The key difference: Nutanix Inc is far larger — about 30.8× Tilray Brands Inc's market cap, and Nutanix Inc is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals.
| NTNX | TLRY | |
|---|---|---|
Market Cap | $18.24B | $591.60M |
Sector | Technology | Health |
52-Week High | $81.12 | $21.00 |
52-Week Low | $34.41 | $3.88 |
Enterprise Value | $17.40B | $758.73M |
Signals from Pluang's Aura AI — not financial advice
Nutanix (NTNX) trades at $67.49, down 0.84% on the day, but maintains a bullish technical outlook with strong support near $66. The company reported robust Q4 2026 earnings, beating EPS estimates with $0.60 versus $0.49 expected, and revenue growth continues to accelerate. Analyst sentiment is overwhelmingly positive with a consensus price target of $77.20 and no sell ratings among 32 analysts covering the stock.
The outlook remains favorable given consistent earnings beats and recognition in Gartner's Magic Quadrant. Key risks include high valuation multiples like EV/EBITDA of 50.5 and competitive pressures in cloud infrastructure. The stock offers upside to consensus targets but requires monitoring of execution against growth expectations.
TLRY trades at $4.30, down 4.44% today, reflecting ongoing investor skepticism despite record fiscal 2026 revenue of $915 million. The stock shows bearish technical signals with key support at $4.00, while fundamentals reveal significant challenges including negative net income margins (-13.26%) and consecutive earnings misses. Recent developments include strategic partnerships expansion in New York and California spirits markets and increased medical cannabis production capacity to 275 metric tonnes.
TLRY faces substantial execution risks with persistent losses and negative cash flow, though trading below book value (P/B 0.37) offers potential value. Analyst consensus remains cautious with 65% hold ratings, while regulatory progress in cannabis remains a key catalyst. The stock requires successful margin improvement and U.S. regulatory clarity for sustained recovery.
Trailing returns across standard periods
Nutanix, Inc. is a global leader in cloud software and hyperconverged infrastructure (HCI) solutions. The company's platform converges computing, virtualization, and storage into a single, seamless software-defined solution, enabling private, hybrid, and multi-cloud environments. Nutanix helps organizations simplify data center operations, manage their applications across various cloud platforms, and reduce IT complexity, positioning it as a key enabler of modern hybrid cloud strategies.
Read more on NTNX →Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →